

www.bioss.com.cn sales@bioss.com.cn techsupport@bioss.com.cn 400-901-9800

ULBP1 Rabbit pAb

Catalog Number: bs-2728R

Target Protein: ULBP1
Concentration: 1mg/ml

Form: Liquid

Host: Rabbit

Clonality: Polyclonal

Isotype: IgG

Applications: WB (1:500-2000), IHC-P (1:100-500), IHC-F (1:100-500), IF (1:100-500)

Reactivity: Human, Rat

Predicted MW: 25 kDa Entrez Gene: 80329

Swiss Prot: Q9BZM6

Source: KLH conjugated synthetic peptide derived from human ULBP1: 121-220/244.

Purification: affinity purified by Protein A

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: N2DL1 is a human rat mouse ligand for the NKG2D receptor, together with at least ULBP2


and ULBP3. ULBPs activate multiple signaling pathways in primary NK cells, resulting in the

production of cytokines and chemokines. Binding of ULBPs ligands to NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. The interaction with UL16 blocks the interaction with the NKG2D receptor, providing a mechanism by which CMV infected cells might escape the immune system. UL16 also causes ULBP1 to be retained in the ER and cis-Golgi apparatus so that it does not reach the cell surface. ULBP1 is expressed in T-cells, B-cells, erythroleukemia cell

lines and in a wide range of tissues.

VALIDATION IMAGES

kD 150— 100— 75— 50— —ULBP1 37— 25— 20Protein: rat kidney lysates, 30ug; Primary: Anti-ULBP1 (bs-2728R) at 1:200; Secondary: HRP conjugated Goat Anti-Rabbit IgG(bs-0295G-HRP) at 1:5000; ECL excitated the fluorescence; Predicted band size: 25kD Observed band size: 43kD



Paraformaldehyde-fixed, paraffin embedded (Rat lymph); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (ULBP1) Polyclonal Antibody, Unconjugated (bs-2728R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (human lung carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (ULBP1) Polyclonal Antibody, Unconjugated (bs-2728R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (human cervical carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (ULBP1) Polyclonal Antibody, Unconjugated (bs-2728R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (human colon carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (ULBP1) Polyclonal Antibody, Unconjugated (bs-2728R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.



Paraformaldehyde-fixed, paraffin embedded (human breast carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (ULBP1) Polyclonal Antibody, Unconjugated (bs-2728R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructions and DAB staining.

PRODUCT SPECIFIC PUBLICATIONS

[IF=5.6] Wanze Zhang, et al. Novaferon gene modification promotes NK92 cell anti-tumor activity. INT IMMUNOPHARMACOL. 2023

